Floatz logo

Larotrectinib

Congenital Fibrosarcoma

BayerSmall moleculeUnknownActive
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Congenital Fibrosarcoma cohort.

Asset / SponsorPhaseRating
Selpercatinib
Eli Lilly and Company
Phase 1/2CCC
bay2757556
Bayer
UnknownD

Same molecule, other indications

Larotrectinib is also rated in:

NTRK fusion positive cancerActive
BB
Indicative · Phase 1/2
65 / 100
View asset →
non-Hodgkin lymphomaActive
CCC
Indicative · Phase 2
53 / 100
View asset →
refractory malignant neoplasmActive
CCC
Indicative · Phase 2
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →